Search
Citations & References (13)
Gibco™
StemPro™ MSC SFM XenoFree
Gibco™ StemPro™ MSC SFMゼノフリーは、完全に無血清および異種（xeno）のない条件下で、ヒト間葉系幹細胞（MSC）および脂肪由来幹細胞詳細を見る
| 製品番号（カタログ番号） | 数量 |
|---|---|
| A1067501 | 1 Kit |
製品番号（カタログ番号） A1067501
価格（JPY）お問い合わせください ›
74,400
Each
数量:
1 Kit
Gibco™ StemPro™ MSC SFMゼノフリーは、完全に無血清および異種（xeno）のない条件下で、ヒト間葉系幹細胞（MSC）および脂肪由来幹細胞（ADSC）の成長と増殖用に開発されました。StemPro™ MSC SFMゼノフリーを使用すると、ヒトMSCまたはADSCは、それらの多能性表現型（すなわち、骨形成、軟骨形成、および脂肪生成系統への分化能）を維持しながら、複数の継代に拡張できます。StemPro™ MSC SFMゼノフリーは、cGMPに準拠しており、トレーサビリティと製造の信頼性を実現します。
研究用にのみ使用できます。診断用には使用いただけません。
仕様
細胞タイプMesenchymal Stem Cells
培養環境CO2
抗生物質を含むNo antibiotics
製品ラインStemPro
製品タイプStem Cell Serum Free Media (SFM)
純度または品質グレードMS Cell-Qualified
数量1 Kit
種Human
分類Xeno-free
Culture TypeAdherent Cell Culture
形状Liquid
Serum LevelSerum-free
添加剤なしNo Glutamine, No Phenol Red
Unit SizeEach
組成および保存条件
Each kit contains 1 x 500 ml StemPro™ MSC SFM Basal Medium and 1 X 5 ml StemPro™ MSC SFM XenoFree Supplement. StemPro™ MSC SFM Basal Medium is stored at 2 to 8°C and stable for 12 months. The StemPro™ MSC SFM XenoFree Supplement is stored frozen at -5 to -20°C and stable for 12 months.
よくあるご質問（FAQ）
What is the concentration of sodium bicarbonate in StemPro MSC SFM XenoFree?
引用および参考文献 (13)
引用および参考文献
Abstract
Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity.
Journal:Molecular therapy : the journal of the American Society of Gene Therapy
PubMed ID:30341012
Exosomes can deliver therapeutic RNAs to neurons. The composition and the safety profile of exosomes depend on the type of the exosome-producing cell. Mesenchymal stem cells are considered to be an attractive cell type for therapeutic exosome production. However, scalable methods to isolate and manufacture exosomes from mesenchymal stem cells
Diverse impact of xeno-free conditions on biological and regenerative properties of hUC-MSCs and their extracellular vesicles.
Journal:Journal of molecular medicine (Berlin, Germany)
PubMed ID:27638341
ABSTRACT: Growing evidence indicates that intracellular signaling mediated by extracellular vesicles (EVs) released by stem cells plays a considerable role in triggering the regenerative program upon transplantation. EVs from umbilical cord mesenchymal stem cells (UC-MSC-EVs) have been shown to enhance tissue repair in animal models. However, translating such results into
Toward a clinical-grade expansion of mesenchymal stem cells from human sources: a microcarrier-based culture system under xeno-free conditions.
Journal:Tissue engineering. Part C, Methods
PubMed ID:21895491
The immunomodulatory properties of mesenchymal stem cells (MSCs) make them attractive therapeutic agents for a wide range of diseases. However, the highly demanding cell doses used in MSC clinical trials (up to millions of cells/kg patient) currently require labor intensive methods and incur high reagent costs. Moreover, the use of
A xeno-free microcarrier-based stirred culture system for the scalable expansion of human mesenchymal stem/stromal cells isolated from bone marrow and adipose tissue.
Journal:
PubMed ID:26136376
'Human mesenchymal stem/stromal cells (MSC) are promising candidates for cell-based therapies and the development of microcarrier-based cultures in scalable bioreactors with well-defined xenogeneic-free components represent important milestones towards the clinical-scale production of these cells. In this work, we optimized our previously developed xeno-free microcarrier-based system for the scalable expansion of
Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media.
Journal:
PubMed ID:26564250
'Due to their immunosuppressive properties, mesenchymal stem cells (MSC) have been evaluated for the treatment of immunological diseases. However, the animal-derived growth supplements utilized for MSC manufacturing may lead to clinical complications. Characterization of alternative media formulations is imperative for MSC therapeutic application. Human BMMSC and AdMSC were expanded in